semaglutide information FDA Approves Oral Semaglutide: First GLP-1 Weight Loss Pill Ozempic® Pen Dosing | Ozempic®

What to Expect in Month 1 Appetite changes: Noticeable suppression begins week 3-4 for most Mild nausea: 40% experience some nausea, usually mild Injection site reactions: Redness, itching, or mild pain at injection site (14% of patients) Fatigue: Some patients report low energy as body adjusts Bowel changes: Either constipation or looser stools as medication affects gut motility 4 Essential Strategies for Month 1 1

This medicine is one of the most exciting changes in obesity medicine ever, says Dr

J., Flynn, M

In early 2026, the FDA also issued warning letters to certain telehealth companies regarding marketing claims about compounded GLP-1 products

DeFronzo RA, Fleck PR, Wilson CA, et al